Education
About Us
Working with TipRanks
Follow Us
Faes Farma SA (GB:0K9H)
LSE:0K9H
0K9H Stock Chart & Stats
€5.23
€0.02(0.63%)
At close: 4:00 PM EST
€5.23
€0.02(0.63%)
Day’s Range― - ―
52-Week Range€3.27 - €5.48
Previous CloseN/A
Volume9.42K
Average Volume (3M)3.41K
Market Cap
€1.57B
Enterprise Value€1.53B
Total Cash (Recent Filing)€111.62M
Total Debt (Recent Filing)€95.65M
Price to Earnings (P/E)14.9
Beta0.54
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding316,223,940
10 Day Avg. Volume1,797
30 Day Avg. Volume3,412
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)1.48
Price to Sales (P/S)2.18
P/FCF Ratio14.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)€703.87M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Capital StructureExtremely low leverage and a high equity ratio provide durable financial flexibility, allowing the company to fund R&D, absorb shocks, and pursue opportunistic M&A without strain. A 15.34% ROE indicates efficient capital use supporting long-term shareholder returns.
Sustainably High Profitability MarginsConsistently strong gross and operating margins signal structural pricing power and cost control across the portfolio. These margins support reinvestment in pipelines, buffer against pricing pressure, and underpin durable cash generation and earnings resilience over multiple market cycles.
Improved Free Cash Flow GenerationThe shift to positive free cash flow and a cash conversion ratio above 1 demonstrates improving cash quality and internal funding capacity. Durable FCF enables capex, R&D funding and shareholder distributions with less reliance on external financing over the medium term.
Bears Say
Exposure To Generic-drug Competitive PressureSignificant exposure to generics creates persistent margin and pricing pressure as competitors erode exclusivity. Over time this structural dynamic requires continuous pipeline investment and branded product development to sustain revenue and protect margins.
Historical Cash-flow VolatilityWhile recent FCF is positive, prior volatility indicates cash generation can swing, which risks funding predictability for R&D, dividends or M&A during downturns. Persistent volatility would constrain long-term planning and elevate financing or liquidity risk.
Dependence On Partnerships And International SalesReliance on licensing, partnerships and international markets exposes revenue to counterparty, regulatory and geopolitical risks. Structural dependency means contract renewals, price controls or market access issues could materially affect medium-term revenue stability.
Faes Farma News
0K9H FAQ
What was Faes Farma SA’s price range in the past 12 months?
Faes Farma SA lowest share price was €3.27 and its highest was €5.48 in the past 12 months.
What is Faes Farma SA’s market cap?
Faes Farma SA’s market cap is €1.57B.
When is Faes Farma SA’s upcoming earnings report date?
Faes Farma SA’s upcoming earnings report date is Feb 27, 2026 which is today.
How were Faes Farma SA’s earnings last quarter?
Currently, no data Available
Is Faes Farma SA overvalued?
According to Wall Street analysts Faes Farma SA’s price is currently Overvalued.
Does Faes Farma SA pay dividends?
Faes Farma SA does not currently pay dividends.
What is Faes Farma SA’s EPS estimate?
Faes Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Faes Farma SA have?
Faes Farma SA has 316,223,940 shares outstanding.
What happened to Faes Farma SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Faes Farma SA?
Currently, no hedge funds are holding shares in GB:0K9H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Faes Farma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.48%
12-Months-Change
Fundamentals
Return on Equity
14.89%
Trailing 12-Months
Asset Growth
19.41%
Trailing 12-Months
Company Description
Faes Farma SA
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
Technical Analysis
Almirall
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---